Corporate Presentation

TAKE Solutions Ltd. Enabling Business Efficiencies

TAKE: Technology, Analytics & Knowledge for the Enterprise

2

Contents

TAKE – At A Glance

Business Model & Market Potential

Competencies

− Life Sciences

− Supply Chain Management

Financials

Growth Strategies & Key TAKEaways

Appendix

3

TAKE Solutions – At A Glance

Headquartered in Chennai, India, TAKE Solutions Ltd. delivers technology, services and expert advice in Life Sciences and Supply Chain Management domains

Strong presence in US, Europe and Middle East Asia: US contributes approx. 2/3 of revenue

CMMi Level 5 accredited company

Recognitions:

TAKE Solutions receives SDCE 100 Award for Third Consecutive Year

TAKE is ranked Leader in the life science R&D IT outsourcing and Drug Safety market by IDC, a premier global provider of market intelligence and advisory services IT markets

Ranked first by a premier global analyst firm, for industry expertise and overall customer satisfaction in Life Sciences domain

“Editors’ Pick” Distinction by Consumer Goods Technology Magazine

We serve 410+ clients through 14 offices globally with 1,100+ employees

Life Sciences: Celgene, Eisai, Johnson & Johnson, Merck, Neuromed, Novartis, Pfizer, Roche, Sanofi Aventis

SCM: Applied Materials, Alcoa, GE Group, Honeywell, Panasonic, ITC, Pepsi, Transocean, Xerox

About TAKE Marquee Clients

Financials

FY14 Revenue : INR 8,217 million

FY14 Net Profit: INR 580 million

0

2,500

5,000

7,500

10,000

FY10 FY11 FY12 FY13 FY14

INR

mill

ion

Revenue Net Profit

4

Global Footprint

Chennai, India Austin, TX

Philadelphia, PA Muscat, Oman

Princeton, NJ

TAKE Solutions Inc. 502 Carnegie Center, Suite 100, Princeton, NJ

USA HQ

TAKE Solutions Ltd. No.8B, Adyar Club Gate Road, Chennai - 600028, India

Global HQ

Riyadh, Jeddah & Al-Khobar

Saudi Arabia

Dubai, UAE

Strong Presence in the US, Middle East Asia and Europe

Hampshire, UK

TAKE Solutions LLP Shriram "The Gateway SEZ", Perungalathur, Chennai, India

Global Delivery Center

Singapore

Abraq Khaitan, Kuwait

5

Recognitions and Partnerships

2014: Ranked 2nd at Asia‘s Best Employer Brand Awards, Singapore.

CMMi Level 5

2013: SDCE 100 Award for Third Consecutive Year

2013: 7th Employer Branding Award for Excellence in Training

2013: IDC ranked TAKE as Leader in the life science Drug Safety Services market based on our ddemonstrated delivery experience, deep understanding of drug safety processes & platforms and deep strategic drug safety expertise

2011: IDC, a global market intelligence firm, ranked TAKE as Leader in the life science R&D IT outsourcing market based on the company’s capabilities and future strategies aligned with what customers will require in three to five years

2011 Supply & Demand Chain Executive 100 list

2010: A premier global analyst firm recognized and ranked TAKE, first among large system integrators for industry expertise & overall customer satisfaction in the Life Sciences Domain

2010 “Editors’ Pick” Distinction by Consumer Goods Technology Magazine

Global Logistics & Supply Chain Strategies 2010: 100 Great Supply Chain Partners List

Oracle Gold Partner

SAP Business Objects Gold Partner

Microsoft BIO IT alliance Partner

CDISC Solutions Partner

Microsoft’s Digital Pharma Initiative

Microsoft High Impact Gold partner

Sparta Systems

Generis

Certifications & Accreditation Alliances and Partnerships

Business Model &

Market Potential

7

TAKE Solutions – Business Model

DOMAIN Supply Chain Management & Life Sciences

TECHNOLOGY

Service Oriented Architecture (SOA)

Cloud Computing

Virtualization

DELIVERY model

REVENUE model

SaaS On

Premise Business Services

Embedded / RFID / Mobile

Licenses

Maintenance

TRANSACTIONS / SUBSCRIPTIONS

Services

8

TAKE Solutions – Business Model

Balanced: Well distributed across two key verticals - niche offerings addressing multiple end user industries

Wide Portfolio of Offerings: Solutions to address customer needs - Solutions delivered as business services, products and SaaS

Diversified Customer Base: Portfolio of solutions to address customer size - focused approach to large & mid-market customer segment and wider approach to SME segment

Scalable: Platform agnostic solutions to enhance addressable markets and strategic partnerships to drive penetration in areas of specialization

Diversified Revenue Streams: Income from subscription, licensing, royalties, services and AMC leading to a mix of annuity and non annuity revenues

9

Total Addressable Market

1.0

8.0

40.0

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

40.0

45.0

SaaS On Premise Business Services

USD

bill

ion

5.7

10.2

0.0

2.0

4.0

6.0

8.0

10.0

12.0

Pre - Approval Post- Approval

USD

bill

ion

Supply Chain Management Life Sciences

Domain Competency

Life Sciences

11

Integrated Solutions & Services

12

Software products - Life Sciences

Clinical Regulatory Safety

Regulatory

Submissions

SPL/PLR

PPM

Safety

eCTD

Clinical Development Bio Statistical

Programming

TRMS

SAS - Bio Statistics

Framework

eTMF

CDISC Accelerators

DMS

Oracle Life Sciences

CTMS, EDC, CDMS, LSH/CDR Argus Safety AERS

13

Customer A

Therapeutic Area 1

Indication A Indication B

Phase1

Study I

Phase2

Study 1

Therapeutic Area 2

Indication C

Customer B

Therapeutic Area 1

Indication D Indication E

Phase1

Study 1 Study 1 Study 1

Phase2

Study 1 Study 1 Study 1

Therapeutic Area 2

Customer C

Therapeutic Area 1

Customer D

Therapeutic Area 1

Established customer relationships; scalable revenue model

Technology + business services

TLFs, Biostatistics, SDTM, ADaM, ISS/ISE, DMCs, SAP, EAC, NDAs

Increasing customer base

Mu

ltip

lyin

g re

ven

ues

14

TAKE Life Sciences - Differentiators

Unique combination of deep domain expertise and technical skills

Market penetration across

Bio-pharmaceutical (branded & generic)

Medical device

CROs

Mature infrastructure across USA and APAC

People

Process

Infrastructure – SAS 70* compliant, validated data center

Strategic partnerships with Oracle and Liquent

TAKE’s differentiated approach to markets

Large and mid-market segment : Functional Service Provider

Small and medium segment : Full Service Provider

* SAS 70 (the Statement on Auditing Standards No. 70) defines the standards an auditor must employ in order to assess the contracted internal controls of a service organization. Service organizations, such as hosted data centers, insurance claims processors and credit processing companies, provide outsourcing services that affect the operation of the contracting enterprise.

15

TAKE Life Sciences - Strategy

Broaden and deepen TAKE LS’ engagements with existing and potential clients by retaining and promoting existing and new portfolio of

solutions in clinical, regulatory, safety and content management to obtain new and/or larger contracts from its clients.

In this direction, TAKE LS is also striving to become an important member of FIPNET community which enables it to work effectively together

with all its clients, pharmaceutical clients, suppliers, partners and regulators.

Enlarge Clients’ Portfolio

1

Commit its resources to focus on US and European clients, ensuring it is at the forefront of regulatory and market developments on multiple

platforms.

Communicate and showcase its abilities to these clients in order to win projects related to LS process outsourcing and consulting.

Focus on US and European clients

2

Leverage on its partners to educate pharmaceutical companies on TAKE LS’ capabilities, for example, in relation to the partners’ platform (e.g.

Oracle) to increase the usage of TAKE LS’ consulting and outsourcing offerings and expand its clientele base.

Leverage on Partnerships

3

Focus on increasing its offerings which can be monetised across delivery platforms e.g. products, services offered over SaaS platforms. These

offerings may be developed inhouse or acquired through mergers and acquisitions.

Enable all offerings to be device agnostic, platform and browser agnostic, to achieve scalability.

Focus on the Balanced Offering

Mix

4

16

TAKE assessed as a LEADER in Life Sciences

Source: 1. IDC MarketScape: Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment, August 2011 2. IDC MarketScape: Worldwide Life Science Drug Safety Services 2013 Vendor Assessment

• Capabilities: Evaluated on current capabilities and how well aligned it is to customer needs

• Strategies: Indicates how well the company’s future strategy aligns with what customers will require in three to five years

Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment

Worldwide Life Science Drug Safety Services 2013 Vendor Assessment

17

Customer Profiles –Market Potential

Pharmaceutical

BiotechnologyConsumer

HealthAnimal Health

CropScience/Agroc

hemicals

MedicalDevices

DietarySupplements

Cosmetics Tobacco Generics

Turnover > $100m 744 172 63 53 116 128 72 60 46 44

Turnover > $250m 476 123 53 44 100 99 56 52 40 40

Turnover > $500m 351 98 41 38 84 81 43 45 35 32

Turnover > $1b 257 88 34 27 71 60 36 35 29 22

257 88 34 27 71 60 36 35 29 22

351

98 41 38

84 81 43 45 35 32

476

123

53 44

100 99 56 52 40 40

744

172

63 53

116 128

72 60 46 44

0

200

400

600

800

1000

1200

1400

1600

1800

2000

Nu

mb

er

of

com

pan

ies

Customer/prospect type

Number of customers/prospects by type

18

Geographical spread of customers/prospects

North America Europe Africa Asia Australasia South America

Generics 49 17 2 13 0 1

Tobacco 48 13 0 9 0 2

Cosmetics 175 1270 3 661 0 5

Dietary Supplements 150 23 2 34 1 1

Medical Devices 285 79 0 16 0 1

Crop Science/Agrochemicals 166 47 2 104 6 30

Animal Health 120 335 0 95 0 3

Consumer Health 83 27 2 20 0 1

Biotechnology 587 162 0 34 8 0

Pharmaceutical 4018 3757 33 3139 107 185

0

1000

2000

3000

4000

5000

6000

7000

Nu

mb

er

of

cust

om

ers

/pro

spe

cts

Geography

Customers/prospects by geography

19

Diverse Customer Base : Life Sciences

Bio-Tech

CROs /

Academic

Pharma

Generics /

OTC

Devices

We serve 7 of top 10 global pharmaceutical companies

Domain Competency

Supply Chain Management

21

TAKE SCM Offerings Overview

● Provides solutions and services catering to four sub-areas of SCM requirements:

Enterprise Mobility & Auto ID: To track raw material movement and automate transactions taking place in warehouses, on docks, shop floors

and in-transit

Value Chain Collaboration: To collaborate with suppliers, contract manufacturers, distributors and retailers by providing a public ecosystem or a

private network of trading-partners

Supply-Chain Execution & Analytics: To streamline the process of material management and inventory control while monitoring and managing

supply-chain performance

● Caters to various industries such as Aerospace and Defense, Automotive, Consumer, Oil and Gas, Pharmaceuticals, Telecommunications etc

Product footprint

Enterprise mobility and WM

Enabling efficient data collection

and guided operations

Supply chain collaboration

Streamlining collaborative business process orchestration

Professional services

Delivering a powerful combination

of industry and technology expertise

Oracle Data Collection and

Warehouse Automation

Mobile Sales & Route Delivery

Barcode & RFID Management and

Compliance

Clinical Information Systems

Contract Manufacturing

Collaboration

3PL and Drop Ship Collaboration

Vendor Managed Inventory

Demand Collaboration &

Purchasing Collaboration Request for Quote Collaboration

Quality Collaboration

E-Invoice & AP Automation

Ship Confirmation Collaboration

Oracle MSCA and WMS

Implementation

Supplier Onboarding/Enablement

Oracle Advanced Supply Chain

Planning

Returns Management Supplier Collaboration Analytics

22

Business Services

Spend Analytics

Supplier Performance

Supplier Selection

Contract Administration

Consulting & Insight NAFTA

Compliance

AP automation

Catalog Services

Supplier Enablement

Invoice Processing

Requisition Processing

Reverse Engineering

Value Engineering

Prototyping Simulation & Testing

Design

Drawing & Documentation

Sourcing Support

Sourcing

Engg. Services

Procurement Operations

23

Business Strategy

Niche Focus – Do what we are good in, highly profitable and which creates shareholder value

We will focus on:

Enterprise mobility products

Collaboration Products

Engineering services

Geographically we will focus on US and few parts of Middle East Asia

24

Diverse Customer Base - Global SCM Customers

Pharma & Medical

Industrial Products/ Services

Consumer Products

High Tech

FMCG / Food

Oil & Gas

Financial Highlights

26

Growth Trends

3,664

5,063

7,188

8,386 8,217

0

3,000

6,000

9,000

FY 2010 FY 2011 FY2012 FY 2013 FY 2014

INR

mn

Total Revenues

324

700

856 795

580

0

300

600

900

FY 2010 FY 2011 FY2012 FY 2013 FY 2014

INR

mn

Net Profit

53% 49% 44% 42% 39%

41% 47% 51% 50% 53%

0%

20%

40%

60%

80%

100%

FY 2010 FY 2011 FY2012 FY 2013 FY 2014

Revenue by Vertical

SCM Life Sciences Others

63% 65% 63% 57% 60%

37% 33% 31% 36% 35%

0%

20%

40%

60%

80%

100%

FY 2010 FY 2011 FY2012 FY 2013 FY 2014

Revenue by Geography

United States Asia RoW

27

Quarterly Growth Trends

2,117 2,071 1,953 1,957

2,109 2,123 1,967

1,615 1,690

-2.8% -2.2%

-5.7%

0.2%

7.7%

0.7%

-7.4%

-17.9%

4.6%

-20.0%

-15.0%

-10.0%

-5.0%

0.0%

5.0%

10.0%

15.0%

20.0%

0

500

1,000

1,500

2,000

2,500

Q2 FY13 Q3 FY13 Q4 FY13 Q1 FY14 Q2 FY14 Q3 FY14 Q4 FY14 Q1 FY15 Q2 FY15

INR

mill

ion

Revenue

Revenue Growth q-o-q (%)

416 383 368 353

382 386 352

313

328

211 178 154 132 151 167 129 130 134

19.7% 18.5% 18.8% 18.0% 18.1% 18.2% 17.9%

19.4% 19.4%

10.0% 8.6% 7.9%

6.8% 7.2% 7.9% 6.6%

8.0% 7.9%

0%

5%

10%

15%

20%

25%

0

100

200

300

400

500

Q2 FY13 Q3 FY13 Q4 FY13 Q1 FY14 Q2 FY14 Q3 FY14 Q4 FY14 Q1 FY15 Q2 FY15

INR

mill

ion

Profitability

Op. EBITDA Net Profit Op. EBITDA Margin (%) Net Margin (%)

28

Share Holding Pattern

Category No of Shares % of Total Q-o-Q

Change (%)

Promoter & Promoter Group

83,672,200 68.4% 0.00%

Public Shareholding

- Institutions

DIIs - 0.0% 0.00%

FIIs 1,947,506 1.6% -0.05%

Trust 2,765,422 2.3% 0.00%

- Non Institutions

Bodies Corporate 13,576,764 11.1% 0.11%

Retail/Others 20,438,108 16.7% -0.06%

TOTAL 122,400,000 100.0%

Shareholding Patterns (Sept 30, 2014)

Promoter & Promoter

Group 68.4%

FIIs 1.6%

Trust 2.3%

Bodies Corporate

11.1%

Retail/Others 16.7%

Growth Strategies

And

Key TAKEaways

30

Key Growth Strategies

Broaden and deepen TAKE’s engagements with existing and potential clients by retaining and promoting existing and new portfolio of

solutions in clinical, regulatory, safety and content management to obtain new and/or larger contracts from its clients.

In this direction, TAKE LS is also striving to become an important member of FIPNET community which enables it to work effectively

together with all its clients, pharmaceutical clients, suppliers, partners and regulators.

Enlarge Clients’

Portfolio

2

Commit its resources to focus on US and European clients, ensuring it is at the forefront of regulatory and market developments on

multiple platforms.

Communicate and showcase its abilities to these clients in order to win projects related to rocess outsourcing and consulting.

Focus on US

and European

clients

3

Leverage on its partners to educate pharmaceutical companies on TAKE’s capabilities, for example, in relation to the partners’ platform

(e.g. Oracle) to increase the usage of TAKE LS’ consulting and outsourcing offerings and expand its clientele base.

Leverage on

partnerships

4

Increase its offerings which can be monetised across delivery platforms e.g. products, services offered over SaaS platforms. These

offerings may be developed in-house or acquired through mergers and acquisitions.

Enable all offerings to be device, platform and browser agnostic, to achieve scalability.

Efficient and

scalable

delivery

platforms

5

1. Fully Integrated Pharmaceutical Network

TAKE will focus on Life Sciences business in the future due to its unique positioning that TAKE has achieved over the years , which is not

easy to replicate

Focus on Life

Sciences

Business

1

31

Key TAKEaways

Strong fundamentals

Domain expertise

Marquee client list

Niche player operating in niche segments

Strong Portfolio of products and services

Growth momentum

Traction in Life Sciences vertical

Sustained growth in order book providing visibility

Improving financials

Traction in revenue and expansion in margins

Improvement in key operating metrics and profitability ratios

32

Appendix

Acronyms Meanings

CTMS Clinical Trial Management System

EDC Electronic Data Capture

CDMS Clinical Data Management System

eDMS Electronic Document Management System

eSub Electronic Submissions

CDR Clinical Data Repository

LSH Life Sciences Hub

PV Pharmacovigilance

IND Investigational New Drug

CTA Clinical Trial Authorization

NDA New Drug Application

PaaS Platform as a Service

ETL Extract Transform and Load

PO collaboration Purchase Order Collaboration

AP automation Accounts Payables Automation

THANK YOU

Disclaimer:

This presentation has been prepared by TAKE Solutions Ltd. (the “Company”) solely for your information and for your use and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose. By attending this presentation, you are agreeing to be bound by the foregoing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials.

Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in Supply Chain Management (SCM) & Life Sciences (LS), disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.

TAKE: Technology, Analytics & Knowledge for the Enterprise

For further information, please contact: Sachin Garg sachingarg@takesolutions.com